Description
3
Receptor targets (GLP-1 · GIP · glucagon)
≥99%
HPLC-verified purity
Molecular Breakdown
Retatrutide — GLP-1 / GIP / glucagon triple agonist (LY3437943)
Retatrutide is a synthetic, lipidated single-chain peptide that simultaneously activates three receptors — GLP-1, GIP, and glucagon — making it a “triple agonist” (or “triple-G”). It is one of the most closely watched compounds in metabolic and energy-balance research. Supplied as a 20 mg lyophilized research vial.
Naming note: Retatrutide is sometimes informally listed as “GLP-3.” That is a misnomer — there is no GLP-3 receptor. Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors.
Rx
Retatrutide
Aliases: LY3437943 · triple-G agonist · triagonist · (informally “GLP-3”)
A lipidated synthetic peptide studied in preclinical models as a simultaneous agonist of the GLP-1, GIP, and glucagon receptors.
TypeTriple-receptor agonist peptide (GLP-1R / GIPR / GCGR)
Dev. nameLY3437943
StructureLipidated single-chain peptide (39 aa)
FormulaC₂₂₁H₃₄₂N₄₆O₆₈
Molar mass≈4731.4 g/mol
CAS2381089-83-2
Vial size20 mg
Storage: Lyophilized, store at −20°C, protected from light. Reconstitute with bacteriostatic water; keep reconstituted vials at 2–8°C.
Research Focus — Metabolic / Incretin
In the published literature, Retatrutide is characterized as the first single molecule to agonize all three incretin/glucagon receptors, and is studied in preclinical models of energy metabolism, glucoregulation, and body-weight regulation. It is what distinguishes a “triple agonist” from single (GLP-1) or dual (GLP-1/GIP) agonists.
GLP-1 receptor agonismGIP receptor agonismGlucagon receptor agonismEnergy-metabolism modelsGlucoregulation researchBody-weight regulation
Selected Research
Published literature
Peer-reviewed studies of the compound itself. Provided for scientific reference; they do not describe this product or authorize any human use.
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept.
Cell Metab. 2022;34(9):1234–1247.e9. PMID 35985340 ↗
Citations are provided for scientific reference only and do not constitute claims about this product.
🧪
Backed by a lot-matched Certificate of Analysis
Every Retatrutide order is tied to a COA for the exact lot in your vial — identity and ≥99% purity confirmed by HPLC / mass spectrometry.
View COAs →
⚠️ For Research Use Only. Sold exclusively as reference material for in-vitro laboratory and educational research. Not evaluated by the FDA; not for human or veterinary use, consumption, diagnosis, treatment, or to prevent any disease.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.